Prandial insulin

Merck Sharp & Dohme LLC · FDA-approved active Small molecule Quality 5/100

Prandial insulin is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently FDA-approved. Also known as: Rapid acting insulin analog, Aspart or glulisine or lispro.

Prandial insulin is used to treat conditions such as type 1 diabetes, type 2 diabetes, and hyperkalemia. It works as an insulin receptor agonist, binding to the insulin receptor to lower blood glucose levels.

At a glance

Generic name	Prandial insulin
Also known as	Rapid acting insulin analog, Aspart or glulisine or lispro
Sponsor	Merck Sharp & Dohme LLC
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
• Application of a Protocol of Personalized Medicine in Patients With Type 2 Diabetes Mellitus and Multiple Doses of Insulin in Routine Clinical Care
• Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation (NA)
• A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) (PHASE1)
• DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes (PHASE4)
• A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar (PHASE2, PHASE3)
• Effect of a Food Supplement on Glycemic Parameters in Patients With Impaired Glucose Metabolism (NA)
• A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Prandial insulin CI brief — competitive landscape report
• Prandial insulin updates RSS · CI watch RSS
• Merck Sharp & Dohme LLC portfolio CI

Frequently asked questions about Prandial insulin

What is Prandial insulin?

Prandial insulin is a Small molecule drug developed by Merck Sharp & Dohme LLC.

Who makes Prandial insulin?

Prandial insulin is developed and marketed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).

Is Prandial insulin also known as anything else?

Prandial insulin is also known as Rapid acting insulin analog, Aspart or glulisine or lispro.

What development phase is Prandial insulin in?

Prandial insulin is FDA-approved (marketed).

Related

• Manufacturer: Merck Sharp & Dohme LLC — full pipeline
• Also known as: Rapid acting insulin analog, Aspart or glulisine or lispro